PSG annihilate Inter Milan to win first UCL Title! Was Kylian Mbappe holding them back?
Advertisement
Christian and Stefano then talk about the midfield battle and how PSG dominated the game from the middle of the field. They also talk about Desire Doue's coming of age performance and how he has announced himself on the biggest of stages.
Christian and Stefano then chat the future of each club and their overall thoughts on this year's Champions League campaign.
(1:30) - PSG shock the world with Inter Milan annihilation
(10:00) - Inter Milan end season on an embarrassing note
(18:00) - Amin El Hassan's joins to celebrate PSG's win
(28:00) - Deșire Doue's CL Final coming of age performance
(33:00) - PSG have found the winning formula
(43:00) - Final CL thoughts
Michael Regan - UEFA/UEFA via Getty Images
🖥️ Watch this full episode on YouTube
Check out the rest of the Yahoo Sports podcast family at https://apple.co/3zEuTQj or at Yahoo Sports Podcasts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Cardano and XRP Whale Activity Hits Multi-Month High Despite Recent Pullback
Bitcoin's drop to $114,600 during the early Asian session on Monday triggered a liquidation spree, but Cardano and XRP whales continued to accumulate despite the crypto market downturn. As the market corrected, XRP and Cardano are down 3.7% and 6.2% in the past 24 hours, CoinGecko data shows. "The recent correction from the last two weeks of exuberance is healthy for the markets,' Max Shannon, senior associate at Bitwise Europe, told Decrypt. On-chain data provides strong evidence for this contrarian trend. A look at Santiment's on-chain whale activity shows strong demand for both XRP and Cardano from large holders. The 50-day average of transactions worth $100,000 or more hit a five-month high for both cryptocurrencies in August. Corroborating this bullish outlook is the increase in high-net-worth investors' Cardano and XRP holdings over the past month, according to the platform. XRP wallets holding 1 million to 10 million tokens added 300 million to their portfolio, bringing their total holdings to 6.72 billion as of August 18. In the same period, ADA cohorts also accumulated 30 million tokens, bringing their total holdings to 5.55 billion. HYPE, SUI Lead Altcoin Losses as Ethereum Dips Under $4,300 At current prices, these outsized XRP and Cardano additions are worth $900 million and $27.3 million, respectively. XRP's year-to-date return hovers around 15%, showcasing the token's dominance. This strength is a result of the successful conclusion of the SEC vs. Ripple lawsuit and favorable regulatory developments. 'In recent months, XRP's performance has been shaped by two opposing forces: regulatory clarity and renewed supply concerns due to the release of 1 billion XRP tokens from escrow,' John Murillo, Chief Business Officer of B2BROKER, told Decrypt. The decline in the net taker volume, the difference between the taker buy and sell volumes, over the past four days, shows seller aggression is reducing. Still, XRP's price has produced a lower low. XRP Army Celebrates Being on 'Right Side of History' as SEC's Ripple Lawsuit Ends 'It signals that selling aggression is fading even as price trades lower - a classic bullish divergence,' Maarten Regterschot, Contributing CryptoQuant analyst, told Decrypt. A similar signal spotted in late July and early August catalyzed a double-digit rally for the token, explained Regterschot. Though Cardano's year-to-date performance is -24%, it has started to pick up steam over the past week after Grayscale's August 12 filing for a Cardano Trust ETF. Its relative performance against Bitcoin hit a four-month high last week, indicating a potential altcoin season scenario, where profits from Bitcoin and Ethereum move into altcoins such as Cardano and XRP, giving rise to explosive trends. Crypto Market Conditions 'Exceptionally Strong' as Bitcoin, Ethereum, XRP Advance Looking ahead, the market's trajectory will be determined by major macroeconomic events this week, which could cause altcoins to have muted performance, explained Shannon. Expectations of a rate cut had driven Bitcoin to an all-time high last week, but the odds of a 25-basis-point rate cut have since dropped from 90% to 85%, the FedWatch tool shows. According to experts who previously spoke to Decrypt, a successful peace talk that leads to the end of the Russia-Ukraine conflict and U.S. Federal Reserve Chair Jerome Powell's speech during the Jackson Hole symposium on Friday, confirming the September rate cut could provide the tailwind required for reigniting the bull run. 'A Fed rate cut is arguably priced in,' Shannon said, but cautioned that there is 'more downside risk' for the current market conditions if there are 'any surprises… it could be negative for crypto assets.'
Yahoo
15 minutes ago
- Yahoo
Repurchases of shares by EQT AB during week 33, 2025
STOCKHOLM, Aug. 18, 2025 /PRNewswire/ -- Between 11 August 2025 and 15 August 2025 EQT AB (LEI code 213800U7P9GOIRKCTB34) ("EQT") has repurchased in total 497,182 own ordinary shares (ISIN: SE0012853455). The repurchases form part of the repurchase program of a maximum of 5,535,521 own ordinary shares for a total maximum amount of SEK 2,500,000,000 that EQT announced on 27 May 2025. The repurchase program, which runs between 18 July 2025 and 26 September 2025, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052. EQT ordinary shares have been repurchased as follows: Date: Aggregated volume (number of shares): Weighted average share price per day (SEK): Aggregated transaction value (SEK): 11 August 2025 75,126 336.2295 25,259,577.42 12 August 2025 106,800 335.9381 35,878,189.08 13 August 2025 104,390 338.6734 35,354,116.23 14 August 2025 97,948 339.8628 33,288,881.53 15 August 2025 112,918 345.5130 39,014,636.93 Total accumulated over week 33 497,182 339.5042 168,795,401.19 Total accumulated during the repurchase program 2,245,457 334.7836 751,742,140.99 All acquisitions have been carried out on Nasdaq Stockholm by Skandinaviska Enskilda Banken AB on behalf of EQT. Following the above acquisitions and as of 15 August 2025, the number of shares in EQT, including EQT's holding of own shares is set out in the table shares Class C shares1 Total Number of issued shares2 1,234,611,900 496,056 1,235,107,956 Number of shares owned by EQT AB3 60,168,067 - 60,168,067 Number of outstanding shares 1,174,443,833 496,056 1,174,939,889 1 Carry one tenth (1/10) of a vote 2 Total number of shares in EQT AB, i.e. including the number of shares owned by EQT AB 3 EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders' meetings A full breakdown of the transactions is attached to this announcement. Contact Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15 EQT Press Office, press@ +46 8 506 55 334 This information was brought to you by Cision The following files are available for download: EQT - Repurchases of shares - Weekly press release Q3 2025_w34 EQT Transactions 20250811 to 20250815 EQT View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
